Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis

被引:11
|
作者
Zhang, Siheng [1 ,2 ]
Qiu, Chao [3 ]
Yu, Hanzhi [4 ]
Xu, Yan [1 ]
Xu, Xiaoming [5 ]
机构
[1] Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou, Zhejiang, Peoples R China
[2] Jinan Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China
[3] Lanzhou Univ, Sch Basic Med Sci, Lanzhou, Peoples R China
[4] Tianjin Med Univ, Sch Basic Med Sci, Dept Pharmacol, Tianjin, Peoples R China
[5] Jining First Peoples Hosp, Dept Gastroenterol, Jining, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
gastric cancer; meta-analysis; neutrophil to lymphocyte ratio (NLR); biomarker; immune checkpoint inhibitors (ICIs); INFLAMMATION;
D O I
10.3389/fonc.2023.1070019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The neutrophil to lymphocyte ratio (NLR) is a cost-effective and easily identifiable inflammatory biomarker that has been shown to be closely associated with tumor prognosis and predict survival in patients with multiple malignancies. However, the predictive value of NLR in patients with gastric cancer (GC) treated with immune checkpoint inhibitors (ICIs) has not been fully explored. Therefore, we conducted a meta- analysis to explore the potential of NLR as a predictor of survival in this population. Methods: We systematically searched the PubMed, Cochrane Library, and EMBASE databases from inception to the present for observational researches on NLR and its relationship with progression or survival in GC patients receiving ICIs. To assess the prognostic significance of NLR on overall survival (OS) or progression-free survival (PFS), we used fixed or random-effect models to derive and combine hazard ratios (HRs) with 95% confidence intervals (CIs). We also examined the relationship between NLR and treatment efficacy by calculating relative risks (RRs) with 95% CIs for objective response rate (ORR) and disease control rate (DCR) in patients with GC receiving ICIs. Results: Nine studies of 806 patients were eligible. OS and PFS data were obtained from 9 and 5 studies, respectively. In nine studies, NLR was associated with poor survival, the pooled HR was 1.98 (95% CI 1.67- 2.35, p < 0.001), indicating a significant association between high NLR and worse OS. We conducted subgroup analyses based on study characteristics to confirm the robustness of our findings. A relationship between NLR and PFS were reported in five studies with a HR of 1.49 (95% CI 0.99- 2.23, p = 0.056), which was not significantly associated. Pooling four studies that examined the correlation between NLR and ORR/ DCR in GC patients, we observed a significant correlation between NLR and ORR (RR = 0.51, p = 0.003), but no significant correlation between NLR and DCR (RR = 0.48, p = 0.111). Conclusion: In summary, this meta-analysis indicates that increased NLR is significantly linked to worse OS in patients with GC receiving ICIs. In addition, lowering NLR can improve ORR. Thus, NLR can serve as a predictor for prognosis and treatment response in GC patients treated with ICIs. Nevertheless, further high-quality prospective studies are required to verify our findings in the future.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: A meta-analysis
    Li, Li-Li
    Pan, Li-Sha
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2023, 39 (08): : 842 - 852
  • [2] Prognostic relevance of platelet lymphocyte ratio (PLR) in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
    Hou, Shufu
    Song, Dandan
    Zang, Yelei
    Hao, Ruiqi
    Li, Linchuan
    Zhu, Jiankang
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [3] Prognostic value of lymphocyte-to-monocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
    Mei, Pingping
    Feng, Wenzhe
    Zhan, Yanrong
    Guo, Xiutian
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [4] Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
    Benedict Sacdalan, Danielle
    Anne Lucero, Josephine
    Lee Sacdalan, Dennis
    ONCOTARGETS AND THERAPY, 2018, 11 : 955 - 965
  • [5] Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
    Zhang, Yongchao
    Liu, Bozhi
    Kotenko, Sergei
    Li, Wei
    MEDICINE, 2022, 101 (32) : E29536
  • [6] Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review
    Guo, Yusheng
    Xiang, Dongqiao
    Wan, Jiayu
    Yang, Lian
    Zheng, Chuansheng
    CANCERS, 2022, 14 (21)
  • [7] Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer patients undergoing neoadjuvant chemotherapy: A systematic review and meta-analysis
    Wei, Zhen-Hua
    Tuo, Min
    Ye, Chen
    Wu, Xiao-Fan
    Wang, Hong-Hao
    Ren, Wen-Zhen
    Liu, Gao
    Xiang, Tian
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (11)
  • [8] Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis
    Yang, Tao
    Hao, Lizheng
    Yang, Xinyu
    Luo, Changyong
    Wang, Guomi
    Cai, Caroline Lin
    Qi, Shuo
    Li, Zhong
    BMJ OPEN, 2021, 11 (09):
  • [9] Prognostic Role of Neutrophil/Lymphocyte Ratio in Resected Gastric Cancer: A Systematic Review and Meta-analysis
    Szor, Daniel Jose
    Dias, Andre Roncon
    Pereira, Marina Alessandra
    Kodama Pertille Ramos, Marcus Fernando
    Zilberstein, Bruno
    Cecconello, Ivan
    Ribeiro-Junior, Ulysses
    CLINICS, 2018, 73
  • [10] Pancreatitis in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
    Koseki, Mako
    Nishimura, Yoshito
    Elias, Evelyn
    Estaris, Jonathan
    Chesta, Fnu
    Takaoka, Kensuke
    Shao, Theresa
    Horita, Nobuyuki
    Fujiwara, Yu
    TARGETED ONCOLOGY, 2024, 19 (06) : 867 - 877